Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...
India Today on MSN6d
A costly hope: The financial burden of a rare genetic disorder in IndiaThe high cost and limited availability of treatment are still major challenges for patients with a rare genetic disorder ...
Children with spinal muscular atrophy (SMA) experience benefits from receiving a disease-modifying gene therapy, but many ...
NICE has rejected routine NHS funding for Roche's Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn't come as a surprise to patient association SMA UK.
Additional pressure was then placed on the brand when Roche launched its daily oral therapy Evrysdi (risdiplam) towards the end of that year at a discount to Biogen's injectable rival. Spinraza ...
A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), ...
Differences in SMA newborn screening practices in the U.S. could impact referral patterns or the timing of therapeutic ...
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback